Clinical trials: Dalteparin
Embolism
Efficacy and Safety of Low-molecular Weight Heparin for Thromboprophylaxis in Acutely Ill Medical Patients
Acutely ill immobilized patients are at a high risk for thromboembolic events including deep venous thrombosis or pulmonary embolism.
- Trial name
- NCT00311753
- Testing
- Certoparin, Heparin
- Where
- 2 sites in Germany, Switzerland
- Volunteers
- 342 people
- Sponsor
- Novartis Pharmaceuticals
Medical Prevention Therapy
Canadian Outpatient VTE Management Registry
Primary Objective: To obtain prospective, clinical practice-based data on how symptomatic VTE is managed with low molecular weight heparin (LMWH) enoxaparin in Canadian outpatient settings.
- Trial name
- RECOVERY (NCT01133002)
- Where
- Canada
- Volunteers
- 915 people
- Sponsor
- Sanofi
Acute Pancreatitis
Continuous Regional Arterial Infusion of Low Molecular Weight Heparin in Patients With Severe Acute Pancreatitis
Our animal studies found that continuous regional arterial infusion (CRAI in the celiac trunk) of low molecular weight heparin (LMWH) could alleviate inflammation, improve global hemodynamics and restore organ function in a…
- Trial name
- CRAI-H (NCT01626911)
- Testing
- Continuous regional arterial infusion of low molecular weight heparin in celiac trunk, General treatment
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Nanjing University School of Medicine
Deep Venous Thrombosis
Low Molecular Weight Heparin vs Direct Oral Anticoagulant After Bariatric Surgery
Extended Venous Thromboemboism Prophylaxis After Bariatric Surgeries: A Comparison Of Low Molecular Weight Heparin With Direct Oral Anticoagulant
- Trial name
- NCT06913595
- Testing
- Direct Oral Anticoagulant., Low Molecular Weight Heparine
- Where
- Egypt
- Volunteers
- 100 people
- Sponsor
- Cairo University
Recurrent Implantation Failure
Anticoagulation Therapies Effect on the Endometrial Blood Flow and Pregnancy Outcomes in Unexplained Recurrent Implantation Failure Women
The aim of the study is to investigate whether Low Dose Aspirin and Low Molecular Weight Heparin could increase the uterine perfusion, and finally improve the implantation and pregnancy rates in patients with unexplained…
- Trial name
- NCT03365466
- Testing
- Low dose aspirin, Low molecular weight heparin, Low dose aspirin plus low molecular weight heparin
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Shanghai First Maternity and Infant Hospital
Stroke, Acute, Atrial Fibrillation
RELAXED: Recurrent Embolism Lessened by Rivaroxaban for Acute Ischemic Stroke
Early recurrence of cardioembolic stroke in patients with atrial fibrillation is common, reaching approximately 6% within 30 days after initial stroke.
- Trial name
- RELAXED (NCT02129920)
- Testing
- This is an observational study
- Where
- Japan
- Volunteers
- 2,000 people
- Sponsor
- Japan Cardiovascular Research Foundation
Low Molecular Weight Heparin, Recurrent Implantation Failure
Effect of Low Molecular Weight Heparin in Freeze-thaw Embryo Transfer Cycles in Women With Recurrent Implantation Failure
Recurrent implantation failure (RIF) is considered a tough problem in assisted reproductive technology (ART) without effective treatments. The effect of low molecular weight heparin (LMWH) in pregnancy outcomes is controversial.
- Conditions
- Low Molecular Weight Heparin, Recurrent Implantation Failure, FET, IVF
- Trial name
- NCT06991530
- Testing
- Low Molecular Weight Heparine
- Where
- China
- Volunteers
- 392 people
- Sponsor
- The Second Hospital of Shandong University
Heparin-Induced Thrombocytopenia
Heparin-Induced Thrombocytopenia Registry
The purpose of the Heparin Induced Thrombocytopenia Registry is to explore the frequency of heparin-induced thrombocytopenia (HIT) at Brigham and Women's Hospital and to assess its mortality rate.
- Trial name
- HIT (NCT00456326)
- Where
- United States
- Volunteers
- 242 people
- Sponsor
- Brigham and Women's Hospital
Thromboembolism
Self-management of Low Molecular Weight Heparin Therapy
There is very little data available on compliance with self-injected low molecular weight heparins (LMWH), but what there is, definitely shows that compliance represents a significant problem.
- Trial name
- NCT00794560
- Testing
- patient education
- Where
- 2 sites in Switzerland
- Volunteers
- 154 people
- Sponsor
- University Hospital, Basel, Switzerland
Myocardial Infarction, Venous Thromboembolism
Comparision Between Activated Partial Thromboplastin Time Versus Anti-Xa Activity in Heparin Monitoring
Background: Unfractionated heparin (UFH) is a sulfated polysaccharide extracted from porcine intestinal mucosa that enhances the inhibitory activity of the natural anticoagulant antithrombin towards most activated clotting…
- Conditions
- Myocardial Infarction, Venous Thromboembolism, Stroke, Bleeding
- Trial name
- CATCH (NCT03426982)
- Testing
- Unfractionated heparin
- Where
- China
- Volunteers
- 700 people
- Sponsor
- Wuhan Asia Heart Hospital
Healthy
Bioequivalence Study of a Generic Enoxaparin Sodium to Clexane® After Single Subcutaneous Dose in Healthy Human Subjects
This is a single-dose, randomized, double-blind, two-period, two-treatment, two-sequence, crossover, balanced, pharmacodynamic (PD) study with 7 days wash-out period.
- Trial name
- NCT05265676
- Testing
- Enoxaparin Sodium (Venus Remedies Limited), Enoxaparin Sodium (Sanofi)
- Where
- India
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Venus Remedies Limited
Pediatric Kidney Transplant Recipients
Dose-adjustment of Enoxaparin by a Bayesian Pharmacological Approach in Pediatric Kidney Transplant Recipients (OPTI-TREX)
Allograft vascular thrombosis is a devastating complication in kidney transplantation in adults and older children. Though uncommon, it is often irreversible and represents the main cause of graft loss within after kidney…
- Trial name
- OPTI-TREX (NCT05672550)
- Testing
- Bayesian based dose adjustment of enoxaparin, Usual dose adjustment of enoxaparin
- Where
- 10 sites in France
- Volunteers
- 50 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Cancer, Rivaroxaban
Venous Thromboembolism Prophylaxis After Gynecological Pelvic Cancer Surgery With Rivaroxaban vs Enoxaparin
The Valeria trial will provide high-quality evidence regarding the efficacy and safety of oral rivaroxaban in thromboprophylaxis after gynecological pelvic cancer surgery in comparison with standard parenteral enoxaparin.
- Conditions
- Cancer, Rivaroxaban, Venous Thromboembolism, Thromboprophylaxis
- Trial name
- VALERIA (NCT04999176)
- Testing
- Rivaroxaban, Enoxaparin
- Where
- Brazil
- Volunteers
- 440 people
- Sponsor
- André Luiz Malavasi Longo de Oliveira
Cancer
Comparison of Two Different Dosages of Low-molecular Weight Heparin in Cancer Patients
In a prospective, randomized, double-blind trial, the effects of two different dosages of LMWH (5000 anti-Xa U od sc and 10 000 anti-Xa U od sc daily) on markers of hemostatic system and thrombin generation will be investigated…
- Trial name
- NCT00375076
- Testing
- enoxaparin
- Where
- Austria
- Sponsor
- Medical University of Vienna
Healthy
Study of Pharmacodynamic Equivalence of Enoxaparin Rovi to Clexane®, in Healthy Volunteers
To demonstrate the pharmacodynamic (PD) equivalence of enoxaparin Rovi (100 mg/mL) 100-mg SC injection to Clexane® (100 mg/mL) 100-mg SC injection in healthy volunteers.
- Trial name
- NCT03363477
- Testing
- Enoxaparin, Clexane
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- Rovi Pharmaceuticals Laboratories
Thrombosis, Venous
A Study to Evaluate the Efficacy and Safety of Fondaparinux for the Prevention of Venous Blood Clots in Patients With a Plaster Cast or Other Type of Immobilization for a Below-knee Injury Not Needing Surgery
The purpose of this study is to evaluate the efficacy and safety of fondaparinux in comparison with a heparin (nadroparin) in preventing deep vein thrombosis (blood clots in the leg veins), whether symptomatic or detected by…
- Trial name
- FONDACAST (NCT00843492)
- Testing
- Fondaparinux sodium, Nadroparin
- Where
- 122 sites in France, Germany and 4 more
- Volunteers
- 1,351 people
- Sponsor
- GlaxoSmithKline
Spinal Cord Injuries, Venous Thromboembolism
Apixaban For Thromboprophylaxis In Patients With Acute Spinal Cord Injury
Thromboprophylaxis options are limited for patients with acute spinal cord injury (SCI) and there are no studies on direct oral anticoagulants (DOACs) for thromboprophylaxis in this population.
- Trial name
- NCT03200613
- Testing
- Apixaban, Low molecular weight heparin
- Where
- Canada
- Volunteers
- 8 people
- Sponsor
- McMaster University
Venous Thromboembolism, Brain Tumors
The Roles of Tissue Factor in Malignant Gliomas
To explore the relationship between tissue factor levels, tumour progression, activation of blood coagulation and venous thromboembolism with malignant glioma
- Trial name
- NCT00201903
- Where
- 6 sites in United States, Canada
- Volunteers
- 30 people
- Sponsor
- Ontario Clinical Oncology Group (OCOG)
Breast Cancer, Colorectal Cancer
Standard Therapy With or Without Dalteparin in Treating Patients With Advanced Breast, Lung, Colorectal, or Prostate Cancer
RATIONALE: Dalteparin may be effective in inhibiting the growth of blood vessels in tumors, decreasing the risk of metastatic cancer, preventing the formation of blood clots, and improving quality of life in treating patients…
- Conditions
- Breast Cancer, Colorectal Cancer, Lung Cancer, Prostate Cancer
- Trial name
- NCT00003674
- Testing
- dalteparin, standard therapy
- Where
- 20 sites in United States, Canada
- Volunteers
- 141 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Cancer, Venous Thromboembolism
WAVe Study - Weight Adjusted Dalteparin for Patients Over 90 kg With Acute Cancer Associated Venous Thromboembolism
Cancer patients that develop blood clots are treated with low molecular weight heparin injections (LMWH). One kind of these LMWHs, dalteparin, has its dose determined based on a patient's weight using a formula of 200…
- Conditions
- Cancer, Venous Thromboembolism, Obesity
- Trial name
- WAVe (NCT03297359)
- Testing
- Dalteparin
- Where
- 5 sites in Canada
- Volunteers
- 92 people
- Sponsor
- Ottawa Hospital Research Institute